Barbara Bradfield, one of the original subjects in research trials for the pharmacogenetic cancer drug Herceptin, has now been stable on the drug for more than 20 years. But such success stories are far too rare to constitute a “golden age” of genetics.
平心而论，对某些患者来说，药物遗传学带来了极大的不同。药物遗传学癌症药物赫赛汀的研究试验原始实验对象芭芭拉·布拉德菲尔德（Barbara Bradfield）因该药而情况稳定地生活了20多年。但类似的成功太罕见，不足以构成遗传学的“黄金时代”。